PharmTech Talk

May 27, 2015
Widespread use and abuse of opioid painkillers is prompting efforts to develop new drugs and formulations that resist abuse while providing relief to legitimate patients.
May 26, 2015
The House Energy Committee’s approval of the 21st Century Cures legislation is only a first step, with critics and collaborators alike lining up to comment.
May 22, 2015
As the biopharma industry awaits FDA’s guidance on biosimilar naming, brand and generic manufacturers establish positions.
May 13, 2015
By Pharmaceutical Technology Editors
With acquisition of Oncaspar portfolio for leukemia from Sigma-Tau Finanziaria, Baxter BioScience adds an oncology infrastructure and biologic.
May 11, 2015
The basic principle behind QbD is that quality should be built into a product with an understanding of the product and process by which it is developed and manufactured along with a knowledge of the risks involved in manufacturing the product and how best to mitigate those risks.
May 04, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Capsugel extends inhaled biotherapeutics delivery capability to Phase 2 clinical trials.
May 01, 2015
The revised "21st Century Cures” proposal includes provisions for research for continuous manufacturing, biomarker development, and NIH funding.
Apr 27, 2015
Pharmaceutical Technology
With the Indian pharmaceutical industry on the rise, manufacturing businesses are working together with European and American partners to harness their longstanding experience and reputation in cleanroom manufacturing for a broader pharmaceutical manufacturing marketplace.
Apr 24, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
As a special session at Interphex 2015 this week made clear, few pharma companies are ready for serialization and aggregation deadlines. The disconnect between pharmaceutical manufacturers and their contract partners poses a special risk.
Apr 22, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
The past six months has seen some major changes to the sterile manufacturing landscape in Europe. There have been a number of exits and acquisitions that have no doubt grabbed headlines, but has anything really changed?